Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid ...
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a small clinical-stage biotechnology company focused on developing therapies for solid tumor cancers, aiming to improve how treatments reach and act within tumors. The company’s central platform centers on an intratumoral delivery concept—creating drug product formulations intended to help destroy cancer cells in a ...Intensity Therapeutics, Inc. (NASDAQ: INTS) is a small clinical-stage biotechnology company focused on developing therapies for solid tumor cancers, aiming to improve how treatments reach and act within tumors. The company’s central platform centers on an intratumoral delivery concept—creating drug product formulations intended to help destroy cancer cells in a way that supports immune-cell engagement within the tumor microenvironment. This approach is designed to address both visible tumor growth and more difficult, less detectable aspects of cancer such as micro-metastatic disease.
The company’s primary experimental compound is INT230-6, which is currently in Phase 2 clinical trials. INT230-6 is being studied for multiple difficult-to-treat solid tumors, including cancers affecting the pancreas, colon, bile duct, and squamous cell tumors, among other tumor types such as sarcoma, breast, and liver cancers. Rather than operating purely as a single-program company, Intensity Therapeutics has formed strategic collaboration efforts to test INT230-6 in combination regimens that align with established immuno-oncology standards.
Reported collaborations include work with Merck (Merck Sharpe & Dohme) to evaluate INT230-6 together with Keytruda (pembrolizumab) for advanced pancreatic, colon, squamous cell, and bile duct malignancies. The company also has collaboration activity with Bristol-Myers Squibb to study INT230-6 combined with Yervoy (ipilimumab) in patients with advanced liver, breast, and sarcoma cancers. In addition, Intensity has a research collaboration involving major academic and medical research organizations, including a randomized controlled Phase II neoadjuvant study of INT230-6 for women with early-stage breast cancer.
From a “business and cost” perspective, Intensity’s profile is typical of a small biotech in development: limited headcount (reported as ~5 full-time and ~7 total employees) and a focus on funding, clinical execution, and partnered research rather than large-scale manufacturing. The company’s financial metrics provided indicate losses and negative profitability measures consistent with R&D-intensive clinical development, where revenue is typically not yet a primary driver and cash burn/financing needs are material. Key performance indicators in the dataset reflect a development-stage operating posture rather than stable operating cash generation.
Leadership is anchored by founder and CEO Lewis H. Bender, who serves as both the company’s strategic and operational leader. As Intensity progresses its Phase 2 program(s), its “next steps” are largely tied to clinical outcomes—such as safety/tolerability, response signals, and potential expansion into additional studies or deeper combination trials through existing and future partnerships. The company operates from Shelton/Shelton-area headquarters in Connecticut and maintains its website at https://www.intensitytherapeutics.com.
Operator: Good morning and welcome to the Intensity Therapeutics Second Quarter 2026 Financial Results Conference Call. Joining the call today is Lewis H. Bender, Intensity's President and CEO, and Joseph Talamo, Intensity's Chief Financial Officer. Shortly before this call, Intensity issued a press release announcing its second quarter 2026 financial results, which is available under the News & Events section of the company's website. Shortly after this webcast, a replay of this call will also be posted. Before we begin, the company reminds you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Intensity Therapeutics. These statements include, but are not limited to, statements relating to the company's expected future plans, cash runway, development activities, projected milestones, business activities, or results. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties is included in the company's earnings release issued today. For a more complete list and description of risk factors, we encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its Forms 10-K, 10-Q, and 8-Ks. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Tuesday, August 11, 2026. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. I will now turn the call over to Mr. Bender, Intensity's President and CEO.
Lewis Bender: Thank you, Betsy, and thank you to everyone for joining us this morning. It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our business development activities, and our plans for the second half of 2026. But first, I will turn the call over to Joe Talamo to discuss our second quarter of 2026 financial results. Joe?
Joseph Talamo: Thanks, Lou, and good morning. I am pleased to join you today to present a summary of our second quarter 2026 financial results. Our research and development expenses were $1.8 million for the second quarter of 2026, compared with $1.5 million for the same prior-year period, reflecting an increase of $292,000, or 19%. Clinical trial expenses, which primarily consist of our Phase III INVINCIBLE-3 study costs, were $1.2 million during the second quarter of 2026, compared with $936,000 in the same prior-year period. As previously reported, we initiated plans in April 2026 to resume enrollment in the INVINCIBLE-3 study in a limited number of U.S. sites after pausing new site activations and patient …
